Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

arting and look forward to continued involvement with this novel approach for the treatment of Fabry disease."

Amigal U.S. Registration Phase 3 Trial Design

The Phase 3 trial will evaluate the efficacy, safety and pharmacodynamics of Amigal in males and females with Fabry disease. This trial will consist of a six-month double-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects who are naive to enzyme replacement therapy (ERT) or who have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day.

The primary endpoint will be the change in the amount of kidney interstitial capillary GL-3 as measured in kidney biopsies using histology. Secondary endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour urine protein).

Additionally, the FDA and Amicus reached agreement on an improved methodology for the histological evaluation of GL-3 in the kidney biopsies. An analysis of the Phase 2 and Phase 2 extension study biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had detectable interstitial capillary GL-3 and that reductions were observed in 8 of the 9 responders.

According to Laura Barisoni, MD, Assistant Professor in Pathology and Medicine, Director, Nephropathology Service, Department of Pathology, New York University School of Medicine, "The Phase 2 data using the improved methodology for histological evaluation of GL-3 in kidney biopsies were very encouraging and provide added confidence in the planned Phase 3 study."

It is expected that approximately 30 clinical sites worldwide will participate in this tria
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 Creekridge Capital, ... of its sales channels by adding two new sales ... as a Regional Sales Manager and Stefanie Stark ... Mr. Puma comes to Creekridge with over 20 ... his role at Creekridge, Mr. Puma will be responsible ...
(Date:6/3/2015)... 2015  The International Confederation of Midwives (ICM) has ... as a standard for midwives trained to ICM,s competency ... in consultation with ICM experts. Direct Relief will provide ... countries. As many as one in 30 ... or childbirth.  Skilled birth attendants such as midwives offer ...
(Date:6/3/2015)... 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... agreement with AbbVie (NYSE: ABBV ) to develop ... Halozyme,s ENHANZE ™ platform. ... receive an initial $23 million payment, followed by ... of up to nine collaboration targets. These payments ...
Breaking Medicine Technology:Creekridge Capital Strengthens Sales Team 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... Patient Record Sharing , and Secure ... Among Physicians , DAYTON, Ohio, Oct. 29 ... (HSI) announce an effort to create virtual teams that connect primary ... care of patients, improving the quality and safety of care while ...
... IRVINE, Calif., Oct. 29 PRO-DEX, INC. (Nasdaq: PDEX ... quarter ending September 30, 2009. In addition, Pro-Dex announced ... renewed, a new marketing director has been hired, a product ... shipments have been made of a newly developed product. , ...
Cached Medicine Technology:Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 2Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 3Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10
(Date:6/3/2015)... June 03, 2015 Visual BI ... solutions, today announced the launch of the second ... for SAP® BusinessObjects™ Design Studio. The Design Studio ... capabilities and advanced functionalities into their dashboarding projects. ... suite, Visual BI is adding key components for ...
(Date:6/3/2015)... The panel of independent experts has spent ... short-listed for the awards presented tonight at TU-Automotive Detroit ... but the best-of-the-best can now be revealed as: , ... Volvo swept rivals aside by taking the coveted Car ... from our panel of expert judges., Stand out comments ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
(Date:6/3/2015)... 03, 2015 For the fourth time in ... ), a full-service advertising agency, has been honored by a ... Commerce. , MCA has been selected as a Semi-Finalist for ... will be honored at a luncheon sponsored by Adcock Financial ... Museum of Art. , “This luncheon will include important information ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Sitting at ... cause discomfort in the back, neck, shoulders and/or wrists. ... musculoskeletal injuries. In addition, recent research links sitting for ... of chronic diseases. Fortunately, three inventors from Oakville, Ontario, ... at a desk. , They have developed a prototype ...
Breaking Medicine News(10 mins):Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2
... Medical Center has just enrolled the first U.S. patient in ... certain kinds of melanoma, a deadly skin cancer that in ... than blocking or killing all rapidly dividing cells, whether malignant ... new class of agents that have been designed to sabotage ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... 30 (HealthDay News) -- Early assessment of rheumatoid arthritis ... the likelihood of disease remission without having to take ... Although DMARDs are considered effective in treating rheumatoid ... been linked to uncommon but serious side effects. ...
... their employer, or through an employed family member,s dependent coverage. ... to a new policy brief from the UCLA Center for ... California Health Interview Survey (CHIS), the brief,s authors found that ... with at least one employed family member or 5.7 ...
... of more than 2 million mammogram screenings performed on nearly ... time show a direct link between reduced hormone therapy and ... invasive breast cancer. The researchers saw such a striking decrease, ... promote breast tumor growth. The declines occurred in ...
... system for Wilson,s disease (WD) provides good diagnostic accuracy ... in children with mild liver disease. In asymptomatic children, ... suggestive of WD, however the penicillamine challenge test (PCT) ... subset. Results of the study appear in the December ...
Cached Medicine News:Health News:International clinical trial tests targeted drug for melanoma 2Health News:Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis 2Health News:5.7 million Californians lack access to job-based coverage 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 3Health News:Scoring system is 93 percent accurate for diagnosing Wilson's disease in pediatric patients 2